About US
Contact us
-
Pfizer's subsidiary Wyeth to pay $784.6m to settle Medicaid rebates issuesPfizer subsidiary Wyeth has agreed to pay $784.6m to settle allegations related to the calculation of Medicaid rebates for its gastric drug Protonix (pantoprazole sodium) between 2001 and 2006. Medic2016/2/19
-
US FDA grants breakthrough status for Roche's ocrelizumab to treat PPMSThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche's investigational medicine, ocrelizumab (OCREVUSTM), for the treatment of primary progressive multiple2016/2/18
-
US FDA refuses to approve Merck's Zetia and Vytorin medicinesThe US Food and Drug Administration (FDA) has refused to approve Zetia and Vytorin, Merck's medicines that are used to reduce the risk of cardiovascular events in patients with coronary heart disease.2016/2/17
-
Sandoz buys rights to Pfizer’s infliximab biosimilar in EEANovartis' generic pharmaceuticals division Sandoz has acquired rights of Pfizer's PF-06438179, a biosimilar of Merck's Remicade (infliximab), in the European Economic Area (EEA), to treat a range of a2016/2/17
-
AstraZeneca, MedImmune, Lilly join U-M to discover new CKD treatmentsAstraZeneca and its global biologics research and development arm MedImmune have entered into collaboration with the University of Michigan and Eli Lilly to discover new therapeutic targets to treat c2016/2/16
-
FDA grants orphan status for ONL Therapeutics' ONL1204 to treat retinal detachmentThe US Food and Drug Administration (FDA) has granted orphan drug designation for ONL Therapeutics' first-in-class small molecule peptide, ONL1204, for the treatment of retinal detachment. ONL1204 is2016/2/16
-
AstraZeneca and Daiichi Sankyo field backlash over Super Bowl OIC awareness adA Super Bowl commercial paid for by AstraZeneca ($AZN) andDaiichi Sankyoto stimulate awareness of opioid-induced constipation (OIC) continues to draw controversy, including from the White House, days2016/2/15
-
Sanofi tried and failed with Afrezza. Why does MannKind still think it can win?Can MannKind ($MNKD) really resurrect its inhaled insulinAfrezza? Sanofi ($SNY), a diabetes powerhouse, tried and failed to make a market for the product. Its drawbacks remain. But as theWall Street J2016/2/15
-
Novartis takes aim at Remicade market with EU biosim rights from PfizerSince acquiringHospira, Pfizer's ($PFE) had a pair ofRemicadebiosimilars on its hands. Now, it's making moves to pare that number down to one, and Novartis ($NVS) will be reaping the benefits. The Sw2016/2/14
-
U.K. slaps GSK with $54.4M fine for decade-old pay-for-delay dealThe U.K.'s Competition and Markets Authority was only formed in 2014, but it didn't mind reaching back more than a decade for evidence to slap GlaxoSmithKline ($GSK) with a $54.4 million (£37.62016/2/14